elotuzumab news

All news on elotuzumab (also known as Empliciti): plants, production capacities, investments and involved companies.

23 July 2026

Johnson & Johnson: TECVAYLI + TALVEY reduce progression risk 89% and death risk 62% in earlier-line RRMM

Phase 3 MonumenTAL-6 shows BCMA+GPRC5D bispecific combo and talquetamab+pomalidomide both significantly improved PFS versus investigator’s choice in patients with 1–4 prior lines.

Who will be producing elotuzumab in the future?

Find out with chemXplore Alpha

Learn more